

4 KEY QUESTIONS IN NEW EXPERIMENTAL TECHNOLOGIES ANSWERED AT SMI'S DRUG DISCOVERY CONFERENCE 2018

SMI Reports: 4 KEY QUESTIONS IN NEW EXPERIMENTAL TECHNOLOGIES ANSWERED AT SMI'S DRUG DISCOVERY CONFERENCE 2018

LONDON, ENGLAND, January 9, 2018 /EINPresswire.com/ -- SMI Reports: 4 KEY QUESTIONS IN NEW EXPERIMENTAL TECHNOLOGIES ANSWERED AT SMI'S DRUG DISCOVERY CONFERENCE 2018

SMI's Drug Discovery conference taking place on 21st and 22nd March 2018, London will discuss the answers to 4 key questions in new experimental technologies within drug discovery.

Hear William Janzen, Executive Director, Lead Discovery, Epizyme, review and compare biological and chemical validation of targets and answer whether CRISPR is enough. You can also hear Reyk Horland, Vice President, Business Development, TissUse GmbH provide multi-organ-on-a-chip solutions with case studies of industrial adoption of multi-organ-on-a-chip models eventually leading to a roadmap towards regulatory validation. To hear more from these experts along with Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience and Christoph Dumelin, Laboratory Head, Novartis Institutes for BioMedical Research, register at <http://www.drug-discovery.co.uk/ein>

Alongside the two-day conference, there will be two pre-conference workshops taking place on Tuesday 20th March 2018. The morning session will be led by Nicolas Clare, Technical Project Leader at Axol Bioscience. He will discuss Induced Pluripotent Stem Cell Derived Models and their use in Drug Discovery. The workshop is aimed at those who would like to understand the revolutionary biological technique of creating induced pluripotent stem cells (Ipsc) from any source material, differentiating them into different cell lineages and their use in drug discovery, either as healthy controls or disease models.

The afternoon workshop will be led by Emanuela Cuomo, Associate Principal Scientist at AstraZeneca who will provide an overview of CRISPR/Cas technologies and how they are applied to drug development. Specific examples will illustrate how genome editing is used in AstraZeneca pipeline to improve target identification and validation; also, how it can be used to predict drug

The SMI Group Proudly Presents Its 2nd Annual... **DRUG DISCOVERY**
21st & 22nd March, 2018 | LONDON, UK
Register online at www.drug-discovery.co.uk

resistance and direct drug optimisation.

For more details about the conference and registration information, visit <http://www.drug-discovery.co.uk/ein>

Drug Discovery
21st – 22nd March 2018
Cophorne Tara Hotel, London, UK
www.drug-discovery.co.uk

---end ---

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Kieran Ronaldson at kronaldson@smi-online.co.uk. For media queries please contact Natasha Boumediene at nboumediene@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Natasha Boumediene
SMi Group
+44 (0) 207 827 6020
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.